Hepatocellular Carcinoma - Pipeline Review, H2 2016

Date: November 30, 2016
Pages: 960
Price:
US$ 2,500.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: HDDA6A0D3B4EN
Leaflet:

Download PDF Leaflet

Hepatocellular Carcinoma - Pipeline Review, H2 2016
Hepatocellular Carcinoma - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hepatocellular Carcinoma - Pipeline Review, H2 2016, provides an overview of the Hepatocellular Carcinoma (Oncology) pipeline landscape.

Hepatocellular carcinoma (HCC) is a type of cancer originates from a liver cell (hepatocyte) which becomes cancerous. This type of cancer occurs more often in men than women. Symptoms include abdominal pain or tenderness, especially in the upper-right part, easy bruising or bleeding, enlarged abdomen and yellow skin or eyes (jaundice). The predisposing factors include alcohol abuse, autoimmune diseases of the liver, hepatitis B or C virus infection, inflammation of the liver that is long-term (chronic) and iron overload in the body (hemochromatosis). Treatment includes surgery, chemotherapy and radiation therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hepatocellular Carcinoma - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Hepatocellular Carcinoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hepatocellular Carcinoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Hepatocellular Carcinoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 16, 69, 42, 4, 62 and 14 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Phase 0, Preclinical and Discovery stages comprises 1, 8, 4, 1, 21 and 2 molecules, respectively.Hepatocellular Carcinoma.

Hepatocellular Carcinoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Hepatocellular Carcinoma (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Hepatocellular Carcinoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Hepatocellular Carcinoma (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Hepatocellular Carcinoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Hepatocellular Carcinoma (Oncology)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Hepatocellular Carcinoma (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Hepatocellular Carcinoma (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Hepatocellular Carcinoma Overview
Therapeutics Development
Hepatocellular Carcinoma - Therapeutics under Development by Companies
Hepatocellular Carcinoma - Therapeutics under Investigation by Universities/Institutes
Hepatocellular Carcinoma - Pipeline Products Glance
Hepatocellular Carcinoma - Products under Development by Companies
Hepatocellular Carcinoma - Products under Investigation by Universities/Institutes
Hepatocellular Carcinoma - Companies Involved in Therapeutics Development
Hepatocellular Carcinoma - Therapeutics Assessment
Drug Profiles
Hepatocellular Carcinoma - Dormant Projects
Hepatocellular Carcinoma - Discontinued Products
Hepatocellular Carcinoma - Product Development Milestones
Appendix 933

LIST OF TABLES

Number of Products under Development for Hepatocellular Carcinoma, H2 2016
Number of Products under Development for Hepatocellular Carcinoma - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Development by Companies, H2 2016 (Contd..1)
Number of Products under Development by Companies, H2 2016 (Contd..2)
Number of Products under Development by Companies, H2 2016 (Contd..3)
Number of Products under Development by Companies, H2 2016 (Contd..4)
Number of Products under Development by Companies, H2 2016 (Contd..5)
Number of Products under Development by Companies, H2 2016 (Contd..6)
Number of Products under Development by Companies, H2 2016 (Contd..7)
Number of Products under Development by Companies, H2 2016 (Contd..8)
Number of Products under Development by Companies, H2 2016 (Contd..9)
Number of Products under Investigation by Universities/Institutes, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..1)
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Development by Companies, H2 2016 (Contd..1)
Products under Development by Companies, H2 2016 (Contd..2)
Products under Development by Companies, H2 2016 (Contd..3)
Products under Development by Companies, H2 2016 (Contd..4)
Products under Development by Companies, H2 2016 (Contd..5)
Products under Development by Companies, H2 2016 (Contd..6)
Products under Development by Companies, H2 2016 (Contd..7)
Products under Development by Companies, H2 2016 (Contd..8)
Products under Development by Companies, H2 2016 (Contd..9)
Products under Development by Companies, H2 2016 (Contd..10)
Products under Development by Companies, H2 2016 (Contd..11)
Products under Development by Companies, H2 2016 (Contd..12)
Products under Development by Companies, H2 2016 (Contd..13)
Products under Development by Companies, H2 2016 (Contd..14)
Products under Investigation by Universities/Institutes, H2 2016
Products under Investigation by Universities/Institutes, H2 2016 (Contd..1)
Hepatocellular Carcinoma - Pipeline by 4SC AG, H2 2016
Hepatocellular Carcinoma - Pipeline by AB Science SA, H2 2016
Hepatocellular Carcinoma - Pipeline by Acceleron Pharma Inc, H2 2016
Hepatocellular Carcinoma - Pipeline by ACROVIS Pharma AG, H2 2016
Hepatocellular Carcinoma - Pipeline by Adaptimmune Therapeutics Plc, H2 2016
Hepatocellular Carcinoma - Pipeline by Advenchen Laboratories LLC, H2 2016
Hepatocellular Carcinoma - Pipeline by Alfact Innovation, H2 2016
Hepatocellular Carcinoma - Pipeline by Amgen Inc, H2 2016
Hepatocellular Carcinoma - Pipeline by AndroScience Corp, H2 2016
Hepatocellular Carcinoma - Pipeline by ArQule Inc, H2 2016
Hepatocellular Carcinoma - Pipeline by Array BioPharma Inc, H2 2016
Hepatocellular Carcinoma - Pipeline by Astellas Pharma Inc, H2 2016
Hepatocellular Carcinoma - Pipeline by Astex Pharmaceuticals Inc, H2 2016
Hepatocellular Carcinoma - Pipeline by AstraZeneca Plc, H2 2016
Hepatocellular Carcinoma - Pipeline by AVEO Pharmaceuticals Inc, H2 2016
Hepatocellular Carcinoma - Pipeline by Bayer AG, H2 2016
Hepatocellular Carcinoma - Pipeline by BeiGene Ltd, H2 2016
Hepatocellular Carcinoma - Pipeline by Bio-Cancer Treatment International Ltd, H2 2016
Hepatocellular Carcinoma - Pipeline by Bioneer Corp, H2 2016
Hepatocellular Carcinoma - Pipeline by Blueprint Medicines Corp, H2 2016
Hepatocellular Carcinoma - Pipeline by Boehringer Ingelheim GmbH, H2 2016
Hepatocellular Carcinoma - Pipeline by Boston Biomedical Inc, H2 2016
Hepatocellular Carcinoma - Pipeline by Bristol-Myers Squibb Company, H2 2016
Hepatocellular Carcinoma - Pipeline by Can-Fite BioPharma Ltd, H2 2016
Hepatocellular Carcinoma - Pipeline by CASI Pharmaceuticals Inc, H2 2016
Hepatocellular Carcinoma - Pipeline by CCRP Therapeutics GmbH, H2 2016
Hepatocellular Carcinoma - Pipeline by Celgene Corp, H2 2016
Hepatocellular Carcinoma - Pipeline by Celldex Therapeutics Inc, H2 2016
Hepatocellular Carcinoma - Pipeline by Celsion Corp, H2 2016
Hepatocellular Carcinoma - Pipeline by China Medical System Holdings Ltd, H2 2016
Hepatocellular Carcinoma - Pipeline by Chroma Therapeutics Ltd, H2 2016
Hepatocellular Carcinoma - Pipeline by Chugai Pharmaceutical Co Ltd, H2 2016
Hepatocellular Carcinoma - Pipeline by Daiichi Sankyo Company Ltd, H2 2016
Hepatocellular Carcinoma - Pipeline by Delcath Systems Inc, H2 2016
Hepatocellular Carcinoma - Pipeline by Dicerna Pharmaceuticals Inc, H2 2016
Hepatocellular Carcinoma - Pipeline by Double Bond Pharmaceutical International AB, H2 2016
Hepatocellular Carcinoma - Pipeline by Eisai Co Ltd, H2 2016
Hepatocellular Carcinoma - Pipeline by Eli Lilly and Company, H2 2016
Hepatocellular Carcinoma - Pipeline by Endocyte Inc, H2 2016
Hepatocellular Carcinoma - Pipeline by Epeius Biotechnologies Corp, H2 2016
Hepatocellular Carcinoma - Pipeline by eTheRNA Immunotherapies NV, H2 2016
Hepatocellular Carcinoma - Pipeline by Exelixis Inc, H2 2016
Hepatocellular Carcinoma - Pipeline by F. Hoffmann-La Roche Ltd, H2 2016
Hepatocellular Carcinoma - Pipeline by Faron Pharmaceuticals Oy, H2 2016
Hepatocellular Carcinoma - Pipeline by Galaxy Biotech LLC, H2 2016
Hepatocellular Carcinoma - Pipeline by Genelux Corp, H2 2016
Hepatocellular Carcinoma - Pipeline by Genoscience Pharma, H2 2016
Hepatocellular Carcinoma - Pipeline by Genosco, H2 2016
Hepatocellular Carcinoma - Pipeline by Gilead Sciences Inc, H2 2016
Hepatocellular Carcinoma - Pipeline by GlaxoSmithKline Plc, H2 2016
Hepatocellular Carcinoma - Pipeline by Golden Biotechnology Corp, H2 2016
Hepatocellular Carcinoma - Pipeline by Green Cross Cell Corp, H2 2016
Hepatocellular Carcinoma - Pipeline by Green Cross Corp, H2 2016
Hepatocellular Carcinoma - Pipeline by H3 Biomedicine Inc, H2 2016
Hepatocellular Carcinoma - Pipeline by HanAll Biopharma Co Ltd, H2 2016
Hepatocellular Carcinoma - Pipeline by HEC Pharm Co., Ltd., H2 2016
Hepatocellular Carcinoma - Pipeline by Horizon Pharma Plc, H2 2016
Hepatocellular Carcinoma - Pipeline by Immune Therapeutics, Inc., H2 2016
Hepatocellular Carcinoma - Pipeline by Immunicum AB, H2 2016
Hepatocellular Carcinoma - Pipeline by Immunitor Inc, H2 2016
Hepatocellular Carcinoma - Pipeline by Immunomedics Inc, H2 2016
Hepatocellular Carcinoma - Pipeline by Immunovative Therapies Ltd, H2 2016
Hepatocellular Carcinoma - Pipeline by In-Cell-Art SAS, H2 2016
Hepatocellular Carcinoma - Pipeline by Inovio Pharmaceuticals Inc, H2 2016
Hepatocellular Carcinoma - Pipeline by Inspyr Therapeutics Inc, H2 2016
Hepatocellular Carcinoma - Pipeline by InteRNA Technologies BV, H2 2016
Hepatocellular Carcinoma - Pipeline by Jenrin Discovery Inc, H2 2016
Hepatocellular Carcinoma - Pipeline by Johnson & Johnson, H2 2016
Hepatocellular Carcinoma - Pipeline by KAHR medical Ltd, H2 2016
Hepatocellular Carcinoma - Pipeline by Karcinolys SAS, H2 2016
Hepatocellular Carcinoma - Pipeline by Kite Pharma Inc, H2 2016
Hepatocellular Carcinoma - Pipeline by Komipharm International Co Ltd, H2 2016
Hepatocellular Carcinoma - Pipeline by Kowa Company Ltd, H2 2016
Hepatocellular Carcinoma - Pipeline by Les Laboratoires Servier SAS, H2 2016
Hepatocellular Carcinoma - Pipeline by Ligand Pharmaceuticals Inc, H2 2016
Hepatocellular Carcinoma - Pipeline by Lixte Biotechnology Holdings Inc, H2 2016
Hepatocellular Carcinoma - Pipeline by MaxCyte Inc, H2 2016
Hepatocellular Carcinoma - Pipeline by MedImmune LLC, H2 2016
Hepatocellular Carcinoma - Pipeline by Medivation Inc, H2 2016
Hepatocellular Carcinoma - Pipeline by Medivir AB, H2 2016
Hepatocellular Carcinoma - Pipeline by Merck & Co Inc, H2 2016
Hepatocellular Carcinoma - Pipeline by Merck KGaA, H2 2016
Hepatocellular Carcinoma - Pipeline by Merrimack Pharmaceuticals Inc, H2 2016
Hepatocellular Carcinoma - Pipeline by Midatech Pharma Plc, H2 2016
Hepatocellular Carcinoma - Pipeline by Millennium Pharmaceuticals Inc, H2 2016
Hepatocellular Carcinoma - Pipeline by Mina Therapeutics Ltd, H2 2016
Hepatocellular Carcinoma - Pipeline by Molecular Partners AG, H2 2016
Hepatocellular Carcinoma - Pipeline by MolMed SpA, H2 2016
Hepatocellular Carcinoma - Pipeline by MultiCell Technologies Inc, H2 2016
Hepatocellular Carcinoma - Pipeline by NormOxys Inc, H2 2016
Hepatocellular Carcinoma - Pipeline by Novartis AG, H2 2016
Hepatocellular Carcinoma - Pipeline by NovaTarg Therapeutics Inc, H2 2016
Hepatocellular Carcinoma - Pipeline by Nymox Pharmaceutical Corp, H2 2016
Hepatocellular Carcinoma - Pipeline by Omeros Corp, H2 2016
Hepatocellular Carcinoma - Pipeline by Oncolys BioPharma Inc, H2 2016
Hepatocellular Carcinoma - Pipeline by OncoMed Pharmaceuticals Inc, H2 2016
Hepatocellular Carcinoma - Pipeline by OncoTherapy Science Inc, H2 2016
Hepatocellular Carcinoma - Pipeline by Oneness Biotech Co Ltd, H2 2016
Hepatocellular Carcinoma - Pipeline by Ono Pharmaceutical Co Ltd, H2 2016
Hepatocellular Carcinoma - Pipeline by Onxeo SA, H2 2016
Hepatocellular Carcinoma - Pipeline by Otsuka Holdings Co Ltd, H2 2016
Hepatocellular Carcinoma - Pipeline by Panacea Pharmaceuticals Inc, H2 2016
Hepatocellular Carcinoma - Pipeline by PepVax Inc, H2 2016
Hepatocellular Carcinoma - Pipeline by Pfizer Inc, H2 2016
Hepatocellular Carcinoma - Pipeline by Pharma Mar SA, H2 2016
Hepatocellular Carcinoma - Pipeline by PharmAbcine Inc, H2 2016
Hepatocellular Carcinoma - Pipeline by PharmaEssentia Corp, H2 2016
Hepatocellular Carcinoma - Pipeline by Provecs Medical GmbH, H2 2016
Hepatocellular Carcinoma - Pipeline by Provectus Biopharmaceuticals Inc, H2 2016
Hepatocellular Carcinoma - Pipeline by RedHill Biopharma Ltd, H2 2016
Hepatocellular Carcinoma - Pipeline by Regulus Therapeutics Inc, H2 2016
Hepatocellular Carcinoma - Pipeline by Rigontec GmbH, H2 2016
Hepatocellular Carcinoma - Pipeline by Saronic Biotechnology Inc, H2 2016
Hepatocellular Carcinoma - Pipeline by Shenogen Pharma Group Ltd, H2 2016
Hepatocellular Carcinoma - Pipeline by Shenzen SiBiono GeneTech Co., Ltd., H2 2016
Hepatocellular Carcinoma - Pipeline by Sillajen Biotherapeutics, H2 2016
Hepatocellular Carcinoma - Pipeline by Taiwan Liposome Company Ltd, H2 2016
Hepatocellular Carcinoma - Pipeline by Tara Immuno-Oncology Therapeutics LLC, H2 2016
Hepatocellular Carcinoma - Pipeline by TC BioPharm Ltd, H2 2016
Hepatocellular Carcinoma - Pipeline by Tessa Therapeutics Pte Ltd, H2 2016
Hepatocellular Carcinoma - Pipeline by Therapure Biopharma Inc, H2 2016
Hepatocellular Carcinoma - Pipeline by Theravectys SA, H2 2016
Hepatocellular Carcinoma - Pipeline by Threshold Pharmaceuticals Inc, H2 2016
Hepatocellular Carcinoma - Pipeline by Tiziana Life Sciences Plc, H2 2016
Hepatocellular Carcinoma - Pipeline by TRACON Pharmaceuticals Inc, H2 2016
Hepatocellular Carcinoma - Pipeline by Tumorend LLC, H2 2016
Hepatocellular Carcinoma - Pipeline by UbiVac LLC, H2 2016
Hepatocellular Carcinoma - Pipeline by VasGene Therapeutics Inc, H2 2016
Hepatocellular Carcinoma - Pipeline by Vaxon Biotech, H2 2016
Hepatocellular Carcinoma - Pipeline by Vect-Horus SAS, H2 2016
Hepatocellular Carcinoma - Pipeline by Verlyx Pharma Inc, H2 2016
Hepatocellular Carcinoma - Pipeline by Vicus Therapeutics LLC, H2 2016
Hepatocellular Carcinoma - Pipeline by Virttu Biologics Ltd, H2 2016
Hepatocellular Carcinoma - Pipeline by Vyriad Inc, H2 2016
Assessment by Monotherapy Products, H2 2016
Assessment by Combination Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Hepatocellular Carcinoma - Dormant Projects, H2 2016
Hepatocellular Carcinoma - Dormant Projects (Contd..1), H2 2016
Hepatocellular Carcinoma - Dormant Projects (Contd..2), H2 2016
Hepatocellular Carcinoma - Dormant Projects (Contd..3), H2 2016
Hepatocellular Carcinoma - Dormant Projects (Contd..4), H2 2016
Hepatocellular Carcinoma - Dormant Projects (Contd..5), H2 2016
Hepatocellular Carcinoma - Dormant Projects (Contd..6), H2 2016
Hepatocellular Carcinoma - Dormant Projects (Contd..7), H2 2016
Hepatocellular Carcinoma - Dormant Projects (Contd..8), H2 2016
Hepatocellular Carcinoma - Dormant Projects (Contd..9), H2 2016
Hepatocellular Carcinoma - Dormant Projects (Contd..10), H2 2016
Hepatocellular Carcinoma - Discontinued Products, H2 2016
Hepatocellular Carcinoma - Discontinued Products (Contd..1), H2 2016
Hepatocellular Carcinoma - Discontinued Products (Contd..2), H2 2016
Hepatocellular Carcinoma - Discontinued Products (Contd..3), H2 2016 940

LIST OF FIGURES

Number of Products under Development for Hepatocellular Carcinoma, H2 2016
Number of Products under Development for Hepatocellular Carcinoma - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Assessment by Combination Products, H2 2016
Number of Products by Top 10 Targets, H2 2016
Number of Products by Stage and Top 10 Targets, H2 2016
Number of Products by Top 10 Mechanism of Actions, H2 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
Number of Products by Top 10 Routes of Administration, H2 2016
Number of Products by Stage and Top 10 Routes of Administration, H2 2016
Number of Products by Top 10 Molecule Types, H2 2016
Number of Products by Stage and Top 10 Molecule Types, H2 2016
Skip to top


Renal Cell Carcinoma - Pipeline Review, H2 2016 US$ 2,000.00 Nov, 2016 · 793 pages

Ask Your Question

Hepatocellular Carcinoma - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: